Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 10:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 10,827 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Abnormalities Clear all
Completed Phase 3 Interventional Results available

Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of Age

NCT04953884
View directory record Official record
Conditions
Von Willebrand Disease
Interventions
Wilate
Drug
Lead sponsor
Octapharma
Industry
Eligibility
Up to 5 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 27, 2026, 10:59 PM EDT
Completed No phase listed Observational

The Role of Connective Tissue Growth Factor in the Development of Kidney Disease After Organ Transplantation

NCT00056784
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
4 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 27, 2026, 10:59 PM EDT
Recruiting Not applicable Interventional

Multisensory Early Oral Administration of Human Milk (M-MILK) for Very Preterm Infants

NCT07216664
View directory record Official record
Conditions
Infant, Premature, Diseases
Interventions
Multisensory early oral administration of human milk
Other
Lead sponsor
Loyola University
Other
Eligibility
23 Weeks to 32 Weeks
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
2
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 27, 2026, 10:59 PM EDT
Terminated No phase listed Observational

Percutaneous Interventions in Adults With CHD

NCT00266916
View directory record Official record
Conditions
Congenital Disorders
Interventions
Not listed
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2006
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 23, 2007 · Synced Oct 27, 2026, 10:59 PM EDT
Completed No phase listed Observational

Natural History Study of Serious Medical Events in PWS

NCT03718416
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Not listed
Lead sponsor
Foundation for Prader-Willi Research
Other
Eligibility
5 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Walnut, California
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Oct 27, 2026, 10:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics Study of Colchicine in Familial Mediterranean Fever (FMF) Patients

NCT01075906
View directory record Official record
Conditions
Familial Mediterranean Fever
Interventions
colchicine sprinkle capsules
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
2 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2012 · Synced Oct 27, 2026, 10:59 PM EDT
Active, not recruiting Phase 2 Interventional

ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis

NCT07011706
View directory record Official record
Conditions
Atopic Dermatitis, Atopic, Dermatitis, AD, Eczema
Interventions
ATI-045, Placebo
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
53
States / cities
Phoenix, Arizona • Tucson, Arizona • Bryant, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 27, 2026, 10:59 PM EDT
Completed Phase 2 Interventional

Nasal Potential Studies Utilizing Cystic Fibrosis Transmembrane Regulator (CFTR) Modulators

NCT01348204
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
quercetin
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
8 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 31, 2012 · Synced Oct 27, 2026, 10:59 PM EDT
Completed Not applicable Interventional Results available

AMPLATZER Duct Occluder II Additional Sizes

NCT03055858
View directory record Official record
Conditions
Patent Ductus Arteriosus
Interventions
ADO II AS (PDA closure)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
3 Days and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
9
States / cities
Los Angeles, California • Orlando, Florida • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 27, 2026, 10:59 PM EDT
Recruiting Not applicable Interventional

Milk for Diabetes Prevention

NCT06513026
View directory record Official record
Conditions
Lactose Intolerance, Lactose Intolerant, Lactase Persistence, Pre-Diabetes, Diabetes Mellitus, Type 2
Interventions
Lactose-Containing Milk, Lactose-Free Milk
Dietary Supplement
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 27, 2026, 10:59 PM EDT
Recruiting Phase 2 Interventional

Study With Phage for CF Subjects With Pseudomonas Lung Infection

NCT06998043
View directory record Official record
Conditions
Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis (CF)
Interventions
BX004, Placebo
Biological · Other
Lead sponsor
BiomX Ltd
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
14
States / cities
Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Oct 27, 2026, 10:59 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Characterization of the Pathogenesis of Primary and Secondary Lymphatic Disorders

NCT02156115
View directory record Official record
Conditions
Lymphangiomatosis, Lymphedema, Lymphangiectasia, Pulmonary Lymphangiectasia
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Oct 27, 2026, 10:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

IV Acetaminophen and Patent Ductus Arteriosus

NCT03008876
View directory record Official record
Conditions
Patent Ductus Arteriosus
Interventions
Acetaminophen, Ibuprofen
Drug
Lead sponsor
Albany Medical College
Other
Eligibility
1 Minute to 2 Weeks
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2019 · Synced Oct 27, 2026, 10:59 PM EDT
Terminated No phase listed Observational

Study of Disease Progression in Adults With Inherited Forms of Spastic Paraplegia

NCT05008874
View directory record Official record
Conditions
AMN, AMN Gene Mutation, X-ALD
Interventions
Natural History Observation
Other
Lead sponsor
SwanBio Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
4
States / cities
Stanford, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 27, 2026, 10:59 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Energy Expenditure and Body Composition in Pseudohypoparathyroidism 1a

NCT01398774
View directory record Official record
Conditions
Pseudohypoparathyroidism Type 1A, Albright Hereditary Osteodystrophy
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
5 Years to 45 Years
Enrollment
519 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Oct 27, 2026, 10:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome

NCT01428297
View directory record Official record
Conditions
Healthy Volunteers, Atopic Dermatitis, Netherton Syndrome
Interventions
BPR277 ointment (controlled application), Placebo (Vehicle), BPR277 ointment, BPR277
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
3
States / cities
New Haven, Connecticut • St Louis, Missouri • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 27, 2026, 10:59 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)

NCT04270682
View directory record Official record
Conditions
CTX
Interventions
Blinded CDCA 250 mg TID, Placebo, Open-Label CDCA 250 mg TID, Rescue Medication CDCA 250 mg TID, CDCA Weight-Based Dose TID
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
1 Month and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
9
States / cities
Aurora, Colorado • Orlando, Florida • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Oct 27, 2026, 10:59 PM EDT
Active, not recruiting Phase 3 Interventional

A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A

NCT05685238
View directory record Official record
Conditions
Haemophilia A, Haemophilia A With Inhibitors
Interventions
Mim8
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
15
States / cities
Los Angeles, California • Aurora, Colorado • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 27, 2026, 10:59 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis

NCT02087943
View directory record Official record
Conditions
Dermatitis, Atopic Dermatitis
Interventions
Apremilast, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
15
States / cities
Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Oct 27, 2026, 10:59 PM EDT
Completed No phase listed Observational

Assessment of Children With Tic Onset in the Past 6 Months

NCT01177774
View directory record Official record
Conditions
Tourette Syndrome, Tourette's Disorder, Chronic Motor or Vocal Tic Disorder, Transient Tic Disorder, Tic Disorders, Provisional Tic Disorder
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
5 Years to 10 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Oct 27, 2026, 10:59 PM EDT
Terminated No phase listed Observational

Congenital Heart Disease Research Registry

NCT00757510
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
Not listed
Enrollment
861 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Oct 27, 2026, 10:59 PM EDT
Enrolling by invitation Not applicable Interventional

Applying Population Management Best Practices to Preventative Genomic Medicine Trial

NCT07053813
View directory record Official record
Conditions
Neoplastic Syndromes, Hereditary
Interventions
Web resources, Personalized outreach
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Denver, Colorado • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 27, 2026, 10:59 PM EDT
Completed No phase listed Observational

Tissue Expansion in Breast Reconstruction Without Drains

NCT03784859
View directory record Official record
Conditions
Breast Cancer, Hereditary Breast and Ovarian Cancer Syndrome, Breast Implant; Complications
Interventions
Insertion of Tissue Expander with Fluid Reservoir
Device
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
21 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2020 · Synced Oct 27, 2026, 10:59 PM EDT
Completed Phase 2 Interventional

A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis

NCT02340234
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab, Placebo, TCS Cream
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Oct 27, 2026, 10:59 PM EDT